NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Lykiri

Re: ATLnsider post# 539427

Sunday, November 27, 2022 1:33:15 PM

Post#
539433
of 539437
Thanks for the link ATLnsider.
Maybe they used Opdivo / Nivolumab (Bristol Meyers Squibb) in the pre-clinical mice study.Poor Man -

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170545661

Followers 51
Posts 6908
Boards Moderated 0
Alias Born 10/30/2015


Poor Man -

Re: Kaizenman post# 539375


ATLnsider

Re: Lykiri post# 539393

Sunday, November 27, 2022 12:51:42 PM

Post#
539421
of 539435
Lykiri, never mind, I believe I have found the link you quoted. But, I would still like for you to answer the 2 questions I posed.

Also, I found this link below for the DCVax-L + Nivolumab + CFR-1R study for the UCLA + Bristol Myers Squibb (BMS) collaboration it appears that the NIH also provided some funding for this study, and the money was budgeted and expended by UCLA:

https://reporter.nih.gov/search/cmeOHFTNlEGR3qDo7Efd5Q/project-details/9983047
Bullish
BULLISH


Sunday, November 27, 2022 12:06:29 PM

Post#
539398
of 539434
Kaizan,

My thoughts are that competitive bidding for the C would be more along the lines of a buyout. This appears to be headed to a more structured transaction with multiple partners for JVs.

There are three major deal groupings in play: The ownership rights to L; the partnership rights for L; and everything to do with the rights for Direct. That’s a lot of moving pieces and assets in play. The C has some role in all of that, plus a role in satisfying the price discovery requirements for an immediate listing.

One thought that comes to mind from your question is how do the BP participants involved in JV avoid anti-trust issues. For instance, if Merck and BMY had any discussions related to agreeing separate partnership rather than bidding against one another for a buyout, that might trigger a price fixing isolation. My guess is LP & LG proposed the conceptual structure for multiple partners, then everyone worked from that same sheet of music.

1 Like


ATLnsider

Re: Lykiri post# 539425

Sunday, November 27, 2022 1:16:32 PM

Post#
539427
of 539435
Thanks Lykiri, I believe these are all different collaborations between UCLA, Merck (Keytruda / Pembrolizumab) and Bristol Meyers Squibb (BMS) (Opdivo / Nivolumab).

Also, I believe the studies are different, some combine DCVax-L + PD-1 inhibitor + CSF-1R inhibitor, and then others also add poly-ICLC

Did you have a chance to view this link?

https://reporter.nih.gov/search/cmeOHFTNlEGR3qDo7Efd5Q/project-details/9983047
Bullish
BULLISH

SkyLimit2022

Member Level
Re: HyGro post# 539432

Sunday, November 27, 2022 1:40:58 PM

Post#
539436
of 539438
Thanks for posting your opinions.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847



https://www.liverpool.ac.uk/systems-molecular-and-integrative-biology/staff/michael-jenkinson/



Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.